Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/20/2023 | $12.00 | Buy | ROTH MKM |
| 6/8/2023 | $17.00 | Speculative Buy | The Benchmark Company |
| 1/24/2022 | $10.00 | Buy | HC Wainwright & Co. |
| 7/26/2021 | $10.00 | Buy | Maxim Group |
8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
10-Q - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $14 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $14 price target.
– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter
– 108 patients have completed 1-year of treatment – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – CUPERTINO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safe
CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA. UBS Global Healthcare Conference Format: Fireside chatDate: Thursday, November 14, 2024Time: 8:00 a.m. PTLocation: Rancho Palos Verdes, CAWebcast Link:
ROTH MKM initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $12.00
The Benchmark Company initiated coverage of Reviva Pharmaceuticals with a rating of Speculative Buy and set a new price target of $17.00
HC Wainwright & Co. initiated coverage of Reviva Pharmaceuticals with a rating of Buy and set a new price target of $10.00
SC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
SC 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
SC 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 - - Statistically significant and clinically meaningful reductions in all major symptom domains and secondary endpoints at week 4 with 50 mg of brilaroxazine vs. placebo - - Generally well-tolerated with a side effect profile comparable to placebo for the 15 and 50 mg doses of brilaroxazine; discontinuation rates for brilaroxazine lower than placebo - - Topline data from 1-year open-label extension (OLE) trial expected Q4 2024 - - Conference call and webcast
ORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Sharps Technology: https://www.redchip.com/assets/access/stss_accessReviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAmerican Resources Corp: https://www.redchip.com/assets/access/arec_accessAbout The RedChip
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Reviva Pharmaceuticals: https://www.redchip.com/assets/access/rvph_accessAridis Pharmaceuticals: https://www.redchip.com/assets/access/ards_accessAbout The RedChip Money Report®The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Rel
4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)